Praxis Precision Medicines, Inc.

PRAX Nasdaq SEC CIK 1689548
Follow Praxis Precision Medicines Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$94.2M −27.5% vs same quarter last year
EPS, diluted −$3.23 +3.9% vs same quarter last year
Operating cash flow −$81.7M −25.6% vs same quarter last year
Operating income −$106.9M −36.4% vs same quarter last year
Revenue by quarter
$7.5M
$0
$0
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$400M−$300M−$200M−$100M$0$100MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$0−$303M
FY24$8.6M−$183M
FY23$2.4M−$123M
FY22$0−$214M
FY21-−$167M
FY20-−$61.8M
FY19-−$35.5M
FY18--
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$249.1M
FY24−$131.8M
FY23−$111.2M
FY22−$185.5M
FY21−$125.6M
FY20−$52.6M
FY19−$33.5M
FY18-